These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 17318526)

  • 1. Coumarin anticoagulants and co-trimoxazole: avoid the combination rather than manage the interaction.
    Schalekamp T; van Geest-Daalderop JH; Kramer MH; van Holten-Verzantvoort AT; de Boer A
    Eur J Clin Pharmacol; 2007 Apr; 63(4):335-43. PubMed ID: 17318526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug-drug interactions with metronidazole and itraconazole in patients using acenocoumarol.
    Becker ML; van Uden RCAE; Giezen TJ; Meijer K; Houtenbos I; van den Bemt PMLA
    Eur J Clin Pharmacol; 2020 Oct; 76(10):1457-1464. PubMed ID: 32524154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overanticoagulation associated with combined use of antibacterial drugs and acenocoumarol or phenprocoumon anticoagulants.
    Visser LE; Penning-van Bees FJ; Kasbergen AA; De Smet PA; Vulto AG; Hofman A; Stricker BH
    Thromb Haemost; 2002 Nov; 88(5):705-10. PubMed ID: 12428081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overanticoagulation associated with combined use of antifungal agents and coumarin anticoagulants.
    Visser LE; Penning-van Beest FJ; Kasbergen AA; De Smet PA; Vulto AG; Hofman A; Stricker BH
    Clin Pharmacol Ther; 2002 Jun; 71(6):496-502. PubMed ID: 12087353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug interactions as a cause of overanticoagulation on phenprocoumon or acenocoumarol predominantly concern antibacterial drugs.
    Penning-van Beest FJ; van Meegen E; Rosendaal FR; Stricker BH
    Clin Pharmacol Ther; 2001 Jun; 69(6):451-7. PubMed ID: 11406743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The risk of overanticoagulation in patients with heart failure on coumarin anticoagulants.
    Visser LE; Bleumink GS; Trienekens PH; Vulto AG; Hofman A; Stricker BH
    Br J Haematol; 2004 Oct; 127(1):85-9. PubMed ID: 15384981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics of anticoagulant therapy and comorbidity related to overanticoagulation.
    Penning-van Beest FJ; van Meegen E; Rosendaal FR; Stricker BH
    Thromb Haemost; 2001 Aug; 86(2):569-74. PubMed ID: 11522005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Possible drug-drug interaction between high-dose esomeprazole and phenprocoumon.
    Becker ML; Franken WP; Karapinar F; Verzijl-Zeegers R; Schalekamp T; van der Hoeven RT
    Eur J Clin Pharmacol; 2015 Dec; 71(12):1461-5. PubMed ID: 26400679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allelic variants of cytochrome P450 2C9 modify the interaction between nonsteroidal anti-inflammatory drugs and coumarin anticoagulants.
    Visser LE; van Schaik RH; van Vliet M; Trienekens PH; De Smet PA; Vulto AG; Hofman A; van Duijn CM; Stricker BH
    Clin Pharmacol Ther; 2005 Jun; 77(6):479-85. PubMed ID: 15961979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of cytochrome P450 2C9 polymorphisms on phenprocoumon anticoagulation status.
    Schalekamp T; Oosterhof M; van Meegen E; van Der Meer FJ; Conemans J; Hermans M; Meijerman I; de Boer A
    Clin Pharmacol Ther; 2004 Nov; 76(5):409-17. PubMed ID: 15536456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of major bleeding during concomitant use of antibiotic drugs and coumarin anticoagulants.
    Penning-van Beest FJ; Koerselman J; Herings RM
    J Thromb Haemost; 2008 Feb; 6(2):284-90. PubMed ID: 18031295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation.
    Schalekamp T; Brassé BP; Roijers JF; Chahid Y; van Geest-Daalderop JH; de Vries-Goldschmeding H; van Wijk EM; Egberts AC; de Boer A
    Clin Pharmacol Ther; 2006 Jul; 80(1):13-22. PubMed ID: 16815313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overanticoagulation associated with combined use of lactulose and acenocoumarol or phenprocoumon.
    Visser LE; Penning-van Beest FJ; Wilson JH; Vulto AG; Kasbergen AA; De Smet PA; Hofman A; Stricker BH
    Br J Clin Pharmacol; 2004 Apr; 57(4):522-4. PubMed ID: 15025752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of dosing algorithms for acenocoumarol and phenprocoumon using clinical factors with the standard care in the Netherlands.
    Zhang Y; de Boer A; Verhoef TI; van der Meer FJ; Le Cessie S; Maitland-van der Zee AH; ;
    Thromb Res; 2015 Jul; 136(1):94-100. PubMed ID: 25971661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential interaction between acenocoumarol and diclofenac, naproxen and ibuprofen and role of CYP2C9 genotype.
    van Dijk KN; Plat AW; van Dijk AA; Piersma-Wichers M; de Vries-Bots AM; Slomp J; de Jong-van den Berg LT; Brouwers JR
    Thromb Haemost; 2004 Jan; 91(1):95-101. PubMed ID: 14691574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of switching from acenocoumarol to phenprocoumon on time in therapeutic range and INR variability: A cohort study.
    van Miert JHA; Veeger NJGM; Ten Cate-Hoek AJ; Piersma-Wichers M; Meijer K
    PLoS One; 2020; 15(7):e0235639. PubMed ID: 32649714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term anticoagulant effects of the CYP2C9 and VKORC1 genotypes in acenocoumarol users.
    Verhoef TI; Redekop WK; Buikema MM; Schalekamp T; Van Der Meer FJ; Le Cessie S; Wessels JA; Van Schie RM; De Boer A; Teichert M; Visser LE; Maitland-Van Der Zee AH;
    J Thromb Haemost; 2012 Apr; 10(4):606-14. PubMed ID: 22252093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Prolonged diminished effect of coumarin derivatives after use of rifampicin].
    Harmsze AM; Deneer VH; Wiltink EH
    Ned Tijdschr Geneeskd; 2007 Sep; 151(35):1945-9. PubMed ID: 17907547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of bleeding and antibiotic use in patients receiving continuous phenprocoumon therapy. A case-control study nested in a large insurance- and population-based German cohort.
    Abbas S; Ihle P; Harder S; Schubert I
    Thromb Haemost; 2014 May; 111(5):912-22. PubMed ID: 24429904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subtherapeutic oral anticoagulant therapy: frequency and risk factors.
    Rombouts EK; Rosendaal FR; van der Meer FJ
    Thromb Haemost; 2009 Mar; 101(3):552-6. PubMed ID: 19277419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.